The rise in plasma TNFα may have served to preferentially induce the expression of the Ceacam1-4L variant through activating NF-κB in the anti-inflammatory M2 macrophages of VECadherin+Cc1fl/fl to enhance innate immunity and limit systemic inflammation that would otherwise drive insulin resistance. The gene discussed is NFKB1; the disease is Insulin resistance.